., N. (2023). Effect of SGLT2 inhibitor (Empagliflozin) on HbA1c in most Prevalent Age Group of Type 2 Diabetic Patients (F. Naim, A. Naeem, I. Mehmood, S. ., & T. Abrar , Trans.). International Journal of Pathology, 20(4), 178-181. https://jpathology.com/index.php/OJS/article/view/802